* Note: Prices are in Million (M) USD.
Description:
Roivant Sciences Ltd (ROIV) is an innovative biopharmaceutical company dedicated to revolutionizing the drug development and commercialization landscape through its unique business model and advanced technologies. The company boasts a robust pipeline that targets significant unmet medical needs across neurology, immunology, and rare diseases, positioning itself to efficiently navigate the complexities of drug development while minimizing costs. Led by a seasoned team and supported by strategic partnerships, Roivant aims to deliver both financial growth and enhanced patient outcomes, making it a compelling opportunity for institutional investors.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $1,423 M
Debt : $11 M
EBITDA : $-261 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Life sciences
Industry: Pharmaceutical preparations
Based on industry, 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Using last 8 overlapping fiscal years (max 20).Average Free Cash Flow: $-785 M
Average Revenue: $31 M
Revenue Converted To Free Cash Flow (%): -2,505.8%
Since Free Cash Flow (FCF) to Revenue percentage is non-positive, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2026-03-31): $8 M
Revenue 5 Years Ago (2021-03-31): $24 M
Total Growth over 5 Years: -65.3%
5-Year Revenue CAGR (Historical): -19.1%
Forward 5-Year CAGR (Tapered): -17.2%
Since historical Revenue CAGR is between 0 - 5, 1 point assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2026-03-31): $694 M
Share Count 5 Years Ago (2022-03-31): $670 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $-1.41
Trailing 12-Month Earnings Per Share (EPS): $-1.50
Average Earnings Per Share (EPS): $0.00
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0.00%
⚠️ Caution: Negative earnings detected — Further research is recommended - Next Fiscal Yr EPS: $-1.41
- Latest/TTM EPS: $-1.50
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Using last 8 valid ROE years (max 20).Average ROE: -21.3%
Since Average ROE is non-positive, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $36.31
52-Week Low: $10.90
Threshold Price (15% Above 52-Week Low): $12.54
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $25,779 M
Since Market Cap is between 10B - 100B, 2 points assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 3% exposure of Total Portfolio.
Warren Buffett's Owners' Earnings:
No positive free cash flow found (TTM or annual) to compute Owners' Earnings per share.
Note: Many fast-growing companies reinvest heavily, so Owners' Earnings may appear low.
Consider other factors in your valuation.
Value-Trade has assigned 8 points to above Roivant Sciences Ltd (ROIV) stock.
Last 1 Years Avg PE 28, Fair Value PE 9, Industry Based PE 14, Risk-Free Anchored PE (25% MoS) 16.78. Based on these 4 values, average assigned is 16.94. The fair value of Roivant Sciences Ltd (ROIV) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
